{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:47:26Z","timestamp":1782384446760,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Soligenix, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00430-1","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:04:17Z","timestamp":1775048657000},"page":"693-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Results from a Pilot Study of HyBryte\u2122 (Topical Synthetic Hypericin) Versus Valchlor\u00ae (Mechlorethamine) in the Treatment of CTCL"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct06149247","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4822-0534","authenticated-orcid":false,"given":"Brian","family":"Poligone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4763-9957","authenticated-orcid":false,"given":"Christopher","family":"Pullion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rumage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6257-6775","authenticated-orcid":false,"given":"Richard","family":"Straube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-3031","authenticated-orcid":false,"given":"Oreola","family":"Donini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4333-7111","authenticated-orcid":false,"given":"Christopher J.","family":"Schaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7990-656X","authenticated-orcid":false,"given":"Elaine S.","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"430_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113343","volume":"195","author":"J Latzka","year":"2023","unstructured":"Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2023. Eur J Cancer. 2023;195:113343. https:\/\/doi.org\/10.1016\/j.ejca.2023.113343.","journal-title":"Eur J Cancer"},{"issue":"16","key":"430_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703\u201314. https:\/\/doi.org\/10.1182\/blood-2018-11-881268. (Erratum in: Blood. 2019 Sep 26;134(13):1112. 10.1182\/blood.2019002852.)","journal-title":"Blood"},{"issue":"4","key":"430_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjd.19252","volume":"184","author":"P Quaglino","year":"2021","unstructured":"Quaglino P, Prince HM, Cowan R, et al. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2021;184(4):722\u201330. https:\/\/doi.org\/10.1111\/bjd.19252.","journal-title":"Br J Dermatol"},{"key":"430_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149:25\u201332.","journal-title":"JAMA Dermatol"},{"key":"430_CR5","unstructured":"Valchlor prescriber information: VALCHLOR (mechlorethamine) gel, for topical use [package insert]. Palo Alto, CA: Helsinn Therapeutics (U.S.), Inc. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202317s009lbl.pdf. Accessed (02\/02\/2026)"},{"issue":"3","key":"430_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","volume":"22","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22(3):407\u201314. https:\/\/doi.org\/10.1007\/s40257-021-00591-x. (Erratum in: Am J Clin Dermatol. 2022 May;23(3):425. 10.1007\/s40257-022-00676-1.)","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"430_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13555-022-00681-6","volume":"12","author":"CV Alexander-Savino","year":"2022","unstructured":"Alexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B. Randomized Mechlorethamine\/Chlormethine Induced Dermatitis\u00a0Assessment Study (MIDAS) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides. Dermatol Ther (Heidelb). 2022;12(3):643\u201354. https:\/\/doi.org\/10.1007\/s13555-022-00681-6.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"430_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1046\/j.1523-1747.2003.12350.x","volume":"121","author":"TE Nijsten","year":"2003","unstructured":"Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol. 2003;121:252\u20138.","journal-title":"J Invest Dermatol"},{"key":"430_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/jamadermatol.2022.2749","volume":"158","author":"EJ Kim","year":"2022","unstructured":"Kim EJ, Mangold AR, DeSimone JA, et al. Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides): the FLASH phase\u00a03 randomized clinical trial. JAMA Dermatol. 2022;158:1031\u20139.","journal-title":"JAMA Dermatol"},{"key":"430_CR10","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaad.2010.02.039","volume":"63","author":"AH Rook","year":"2010","unstructured":"Rook AH, Wood GS, Duvic M, Vonderheid EC, Tobia A, Cabana B. A phase\u00a0II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol. 2010;63:984\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"430_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154654","volume":"111","author":"JJ Wu","year":"2023","unstructured":"Wu JJ, Zhang J, Xia CY, et al. Hypericin: a natural anthraquinone as promising therapeutic agent. Phytomedicine. 2023;111:154654.","journal-title":"Phytomedicine"},{"key":"430_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.1523-1747.1998.00278.x","volume":"111","author":"FE Fox","year":"1998","unstructured":"Fox FE, Niu Z, Tobia A, Rook AH. Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol. 1998;111:327\u201332.","journal-title":"J Invest Dermatol"},{"key":"430_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/jvc2.442","author":"CV Alexander-Savino","year":"2024","unstructured":"Alexander-Savino CV, Rumage A, Pullion C, et al. Compatibility study of topical 0.25% hypericin (HyBryte\u2122) application in subjects with mycosis fungoides: results of the HPN-CTCL-02 study. JEADV Clin Pract. 2024. https:\/\/doi.org\/10.1002\/jvc2.442.","journal-title":"JEADV Clin Pract"},{"key":"430_CR14","first-page":"581","volume":"137","author":"M Duvic","year":"2001","unstructured":"Duvic M, Martin AG, Kim Y, et al. Phase\u00a02 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137:581\u201393.","journal-title":"Arch Dermatol"},{"key":"430_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713\u201322.","journal-title":"Blood"},{"key":"430_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamadermatol.2014.3513","volume":"151","author":"VL Pascoe","year":"2015","unstructured":"Pascoe VL, Enamandram M, Corey KC, et al. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151:375\u201381.","journal-title":"JAMA Dermatol"},{"key":"430_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.2021012057","volume":"140","author":"EA Olsen","year":"2022","unstructured":"Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140:419\u201337.","journal-title":"Blood"},{"key":"430_CR18","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29:2598\u2013607.","journal-title":"J Clin Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00430-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00430-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00430-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:53:24Z","timestamp":1782381204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00430-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00430-1","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mr. Adam Rumage and Drs. Christoper Pullion, Richard Straube, Oreola Donini and Christopher Schaber are employed by Soligenix. Dr. Elaine S. Gilmore reports research grants and consulting fees from Soligenix. Dr. Brian Poligone reports research grants and consulting fees from Soligenix, and serves on the Medical Advisory Board for Soligenix, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the WCG institutional review board (IRB) (Puyallup, Washington, USA). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. All patients in this manuscript have given written informed consent for participation in the study and the use of their de-identified, anonymized, aggregated data and their case details for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}